Drug intelligence / Profile preview

CT-044

Development stage: Phase 2
Lead developer: Acadia Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

CT-044 is a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) that targets and catalytically removes peroxynitrite and hydrogen peroxide. It is designed to disrupt cascades initiated by peroxynitrite that lead to neuronal hypersensitivity, providing long-duration pain relief without opioid-related side effects.

Other names: ebaresdax hydrochloride

Beyond the preview

Go deeper on CT-044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-044.

Explore the full profile